5 targeted drugs for the treatment of Thrombocytopenia

Date:2023-04-06 Views: 406 Times

There are several targeted drugs that can be used for the treatment of thrombocytopenia, which is a condition characterized by low platelet count. These drugs work by stimulating platelet production or preventing platelet destruction. Some examples include:

Thrombopoietin (TPO) receptor agonists:

These drugs, such as Eltrombopag and Romiplostim, stimulate the production of platelets by binding to and activating the TPO receptor on the surface of bone marrow cells.


Eltrombopag is a thrombopoietin receptor agonist that stimulates the production of platelets in the bone marrow. It is used to treat thrombocytopenia in patients with chronic immune thrombocytopenia, hepatitis C-associated thrombocytopenia, and severe aplastic anemia.

Approval Statushttps://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022291s027lbl.pdf
Instructions for use:dosing, indications, interactions...etc.https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022291s027lbl.pdf#page=18


 Avatrombopag is also a thrombopoietin receptor agonist that is used to prevent bleeding in patients with chronic liver disease who are undergoing a medical or dental procedure.

Approval Statushttps://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf
Instructions for use:dosing, indications, interactions...etc.https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf#page=10


Lusutrombopag is a thrombopoietin receptor agonist that is used to treat thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a medical or dental procedure.

Approval Statushttps://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210745s000lbl.pdf
Instructions for use:dosing, indications, interactions...etc.https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210745s000lbl.pdf#page=8


Romiplostim is a thrombopoietin receptor agonist that stimulates the production of platelets in the bone marrow. It is used to treat thrombocytopenia in patients with chronic immune thrombocytopenia and in patients with myelodysplastic syndrome.

Approval Statushttps://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125268s059lbl.pdf
Instructions for use:dosing, indications, interactions...etc.https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125268s059lbl.pdf#page=10


Fostamatinib is a spleen tyrosine kinase inhibitor that is used to treat thrombocytopenia in patients with chronic immune thrombocytopenia who have had an insufficient response to other treatments.

Approval Statushttps://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203276s000lbl.pdf
Instructions for use:dosing, indications, interactions...etc.https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203276s000lbl.pdf#page=9


Immunoglobulin (IVIG)

IVIG is a blood product that contains antibodies against platelet-depleting factors. It can be used to prevent the destruction of platelets in certain autoimmune disorders.


In some cases, surgical removal of the spleen can be an effective treatment for thrombocytopenia, as the spleen is responsible for filtering and removing damaged platelets from the bloodstream.

It is important to note that the choice of targeted drug for the treatment of thrombocytopenia will depend on the underlying cause of the condition and the individual patient's medical history and needs. Therefore, it is essential to consult with a healthcare professional for proper diagnosis and treatment.